Lb Pharmaceuticals (LBRX) Research & Development (2024 - 2026)

Lb Pharmaceuticals' Research & Development history runs 3 years deep, the most recent figure standing at $14.6 million for Q1 2026.

• On a quarterly basis, Research & Development rose 328.09% year-over-year to $14.6 million in Q1 2026; TTM through Mar 2026 was $29.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $16.7 million, down 67.28% from the prior year.
• Research & Development advanced to $14.6 million in Q1 2026 per LBRX's latest filing, from $8.5 million in the prior quarter.
• Across five years, Research & Development topped out at $14.6 million in Q1 2026 and bottomed at $376000.0 in Q4 2024.
• The 3-year median for Research & Development is $6.0 million (2025), against an average of $6.7 million.
• Biggest YoY gain for Research & Development was 2156.12% in 2025; the steepest drop was 77.32% in 2025.
• Year by year, Research & Development stood at $376000.0 in 2024, then jumped by 2156.12% to $8.5 million in 2025, then soared by 72.64% to $14.6 million in 2026.
• Per Business Quant, the three latest LBRX Research & Development figures stand at $14.6 million (Q1 2026), $8.5 million (Q4 2025), and $2.4 million (Q3 2025).